-- Duopharma Biotech Contributes to National Pharmaceutical Self-Reliance Through Manufacturing Capacity and Portfolio Growth
- Business roadmap supports regional market ambitions and aligns with goals of New Industrial Master Plan 2030 and 13th Malaysia Plan
Duopharma Biotech Berhad ("Duopharma Biotech" or "the Company") held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024. The sustained double-digit growth was primarily driven by resilient demand from both the public and private sectors across all business segments, complemented by a one-off surge in insulin supply. Profit Before Tax ("PBT") saw markedly strong growth, rising 43.6% year-on-year, and breaching RM100 million for the first time to hit RM114.91 million. In addition to higher revenue, the performance was mainly due to continued favourable API costs, positive foreign exchange movements and improved operational efficiency.
Consequently, the Board of Directors announced a second interim dividend of 3.05 sen per share (FY2024: 2.0 sen), adding to the first interim dividend of 1.5 sen (FY2024: 1.0 sen) per share, bringing the total dividend for FY2025 to 4.55 sen (FY2024: 3.0 sen) per share). The total dividend payout of RM43.77 million (FY2024: RM28.86 million), comprising approximately 50% of the total Profit After Tax, was 51.7% higher year-on-year, demonstrating the Company’s commitment to attractive shareholder returns.
Duopharma Biotech Chairman Datin Paduka Kartini Haji Abdul Manaf commented: “As a Malaysian pharmaceutical leader and Government-linked Corporation, Duopharma Biotech is proud to play our role in ensuring Malaysia’s healthcare ecosystem remains resilient amidst global uncertainties, supporting national priorities by ensuring reliable access to high quality, locally-manufactured medicines for everyone. We aim to provide smarter solutions for a healthier life, via a broader product portfolio, Halal offerings that meet consumer needs and enhanced manufacturing capacity. Guided by the pillars of our ESG Strategy including Sustainable Supply Chain and Access to Medicine, our offerings target to meet growing domestic needs, such as the many Malaysians living with diabetes, hypertension and high cholesterol highlighted in the recently published National Health and Morbidity Survey ("NHMS") 2025.”
Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid remarked, “2025 was a strong year of business performance where Duopharma Biotech continued to ensure a reliable supply of medicines in-country, as well as in our international markets. This was supported by having robust domestic manufacturing capacity in pharmaceuticals which is critical in safeguarding medicine supply in Malaysia. We can see the Government’s attention through major national policies such as the 13th Malaysia Plan ("RMK-13") that encourages domestic manufacturing and greater self-reliance in pharmaceutical supply chains, as well as the New Industrial Master Plan 2030 ("NIMP 2030") that earmarks the pharmaceutical sector as a Key Growth Segment, aiming to enhance the manufacturing of biologics, generics and active pharmaceutical ingredients ("API"), as well as the production of Halal medicines. At Duopharma Biotech, we will continue expanding our portfolio via new products developed in-house and partnerships with innovative technology players.”
A Strategic and Comprehensive Portfolio
In FY2025, the Company achieved a significant milestone by becoming the first company in the world to obtain Halal certification from JAKIM for its biologic product, namely an erythropoietin biosimilar used in the treatment of anaemia among chronic kidney disease patients. In FY2026, the Company will continue expanding its portfolio for treating non-communicable and chronic conditions. The focus on diversification continued in Consumer Healthcare, with the introduction of CHAMPS® Nutribar to offer Vitamin C added as a healthy snack for children, and FLAVETTES® MsRange powdered food supplement for beauty and wellness in women. In addition, the new PROVITON® STR offered energy gels for revitalisation and endurance in sports.
Duopharma Biotech remains a key supplier to the Ministry of Health ("MOH"), currently supplying pharmaceutical and non-pharmaceutical products in the Approved Products Purchase List ("APPL") to Government-operated healthcare facilities until 31 December 2026. The company is also contracted to supply Insulin Aspart to MOH facilities from 6 February 2026 to 5 February 2028, valued at about RM53 million, and recently completed a three-month interim contract (with partner Biocon) to supply Recombinant Human Insulin to MOH facilities from 16 February to 15 May 2026, valued at approximately RM65 million.
Changes in Leadership
FY2025 witnessed key changes in Duopharma Biotech’s Senior Management and Board of Directors. Wan Amir-Jeffery Bin Wan Abdul Majid was appointed Group Chief Executive Officer, taking over from former Group Managing Director Leonard Ariff Bin Abdul Shatar, while Rohayu Rosnani Binti Mohd Adanan took over the Chief Financial Officer position from Chek Wu Kong. In addition, Noor Aida Binti Jaafar was promoted to Chief Commercial Officer.
The Board of Directors welcomed four new Independent Directors: Datuk Wira Arham Bin Abdul Rahman (Senior Independent Non-Executive Director), Dato’ Adnan Hisham Bin Pawanteh, Dr Sharmila A/P Ramachandran and Dr Hasnita Binti Hashim, as well as Non-Independent Director Mohamad Idros Bin Mosin. They replaced outgoing Board members Razalee Bin Amin, Datuk Nik Moustpha Bin Haji Nik Hassan, Zaiton Binti Jamaluddin, Dato’ Dr Zaki Morad Bin Mohamad Zaher, Mohd Haris Bin Mohd Arshad and Dato’ Eisah Binti A. Rahman.
Continued Recognition
Across FY2025, Duopharma Biotech continued to garner accolades. Key wins include the Prime Minister’s Award (Private Sector) and the Gold Award (Private Sector) at the Integrity, Governance and Anti-Corruption Award ("AIGA") 2025 by the Malaysian Institute of Integrity. At the MSWG National Corporate Governance & Sustainability Awards ("NACGSA") 2025, the Group was ranked among the Top 20 companies for Overall Excellence and received the Mid Cap Excellence Award for companies with market capitalisation between RM1 billion and RM2 billion.
The Company was also honoured with the Excellence Award (Silver) for companies with less than RM2 billion in market capitalisation at the National Annual Corporate Report Awards ("NACRA") 2025, and received international recognition with the Excellence in Governance (ESG) Award at the CSIA Global Governance Awards 2026 and the Technology & Innovation Excellence Award at the World Halal Excellence Award ("WHEA").
On the Human Resource front, Duopharma Biotech emerged Champion in the Graduates’ Choice of Employer (Pharmaceutical) category at the 8th Talentbank Graduates’ Choice Awards 2026, a heartening endorsement of trust among youths, after coming in second in the previous six years. Meanwhile, the Company’s established consumer brands continued to be recognised, with CHAMPS® Vitamin C named the Most Voted Kid’s Supplement in the Guardian Awards 2025’s Fan Favourites segment, while UPHAMOL® and FLAVETTES® respectively took Silver and Bronze in the Health category at the Putra Aria Brand Awards 2025.
Release ID: 89192695
Google
RSS